Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
Journal of Clinical Oncology, 07/06/2012
Younes A et al. – Using an every 3–week–schedule of SAR3419 for six cycles, the maximum–tolerated dose (MTD) is 160mg/m2. SAR3419 can be safely administered to patients with relapsed B–cell lymphoma and demonstrates promising clinical activity, including patients who were refractory to rituximab.